Gross Profit Trends Compared: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.

Bristol-Myers vs. Halozyme: A Decade of Profit Growth

__timestampBristol-Myers Squibb CompanyHalozyme Therapeutics, Inc.
Wednesday, January 1, 20141194700000052602000
Thursday, January 1, 201512651000000105812000
Friday, January 1, 201614481000000113485000
Sunday, January 1, 201714710000000285461000
Monday, January 1, 201816014000000141726000
Tuesday, January 1, 201918067000000150446000
Wednesday, January 1, 202030745000000224227000
Friday, January 1, 202136445000000361897000
Saturday, January 1, 202236022000000520812000
Sunday, January 1, 202334313000000636892000
Monday, January 1, 202436351000000855907000
Loading chart...

Cracking the code

Gross Profit Trends: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, Bristol-Myers Squibb Company and Halozyme Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, Bristol-Myers Squibb has demonstrated a robust growth trajectory, with its gross profit surging by nearly 187% from 2014 to 2023. This growth is particularly notable in 2020, where the company saw a significant leap, likely driven by strategic acquisitions and product innovations.

Conversely, Halozyme Therapeutics, Inc., while smaller in scale, has shown a steady upward trend, with its gross profit increasing by over 1,100% during the same period. This remarkable growth, albeit from a smaller base, underscores Halozyme's potential in niche markets and innovative drug delivery solutions.

These trends highlight the diverse strategies and market positions of these two companies, offering valuable insights into their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025